Merus

Yahoo Finance • 2 hours ago

Stocks Finish Higher as Bond Yields Slip and Chip Makers Climb

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) on Monday closed up +0.26%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/f... Full story

Yahoo Finance • 5 hours ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, BRY, SMLR on Behalf of Shareholders

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to sharehold... Full story

Yahoo Finance • 6 hours ago

Stocks Climb on Lower Bond Yields and Strength in Chip Makers

The S&P 500 Index ($SPX) (SPY) today is up +0.42%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.04%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.85%.  December E-mini S&P futures (ESZ25) are up +0.41%, and December E-mini N... Full story

Yahoo Finance • 6 hours ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Electronic Arts Inc. (Nasdaq – EA), Merus N.V. (Nasdaq – MRUS), Berry Corporation (Nasdaq – BRY), Semler Scientific, Inc. (Nasdaq – SMLR)

BALA CYNWYD, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ac... Full story

Yahoo Finance • 7 hours ago

Stocks making the biggest moves midday: CSX, Electronic Arts, Pony AI, Merus & more

Check out the companies making the biggest moves midday: CSX — the railroad operator rose more than 3% after it named Steve Angel chief executive , replacing Joe Hinrichs. The management shake-up follows pressure by activist investor Ancor... Full story

Yahoo Finance • 8 hours ago

Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus

Genmab, on Monday, announced its plan to buy Merus for about $8 billion. The news sent Merus stock into the stratosphere. Continue Reading View Comments... Full story

Yahoo Finance • 9 hours ago

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction representing a transaction value of appro... Full story

Yahoo Finance • 13 hours ago

Stocks Set to Open Higher as Bond Yields Fall, Trump’s Shutdown Talks in Focus

December S&P 500 E-Mini futures (ESZ25 [https://www.barchart.com/futures/quotes/ESZ25]) are up +0.48%, and December Nasdaq 100 E-Mini futures (NQZ25 [https://www.barchart.com/futures/quotes/NQZ25/overview]) are up +0.63% this morning, poin... Full story

Yahoo Finance • 18 hours ago

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billionProposed acquisition adds petosemtamab, a late-stage asset with two Breakthro... Full story

Yahoo Finance • 23 hours ago

Genmab reportedly nearing deal to acquire cancer drug developer Merus

[M&A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] Danish biotech Genmab (GMAB [https://seekingalpha.com/symbol/GMAB]) is in advanced discussions to acquire Merus (NASDAQ:MRUS [https://seekingalpha.com... Full story

Yahoo Finance • 2 months ago

Merus annonce ses résultats financiers pour le deuxième trimestre 2025 et fait le point sur ses activités

- Le pétosemtamab en association avec le pembrolizumab dans un essai de phase 2 mené chez 43 patients atteints d’un CETC r/m PD-L1+ en première intention a permis d’obtenir un taux de réponse de 63 %et un taux de survie globale de 79 % à 1... Full story

Yahoo Finance • 2 months ago

Merus gibt die Finanzergebnisse für das zweite Quartal 2025 bekannt und informiert über die aktuelle Geschäftsentwicklung

– Petosemtamab in Kombination mit Pembrolizumab als Erstlinienbehandlung des PD-L1-positiven rezidivierenden/metastasierten Plattenepithelkarzinoms des Kopfes und Halses zeigt in Phase-II-Studie eine Ansprechrate von 63 %bei 43 auswertbare... Full story

Yahoo Finance • 2 months ago

Merus to Present at the Canaccord Genuity 45th Annual Growth Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclon... Full story

Yahoo Finance • 2 months ago

Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update

-Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial demonstrates 63% response rate observed among 43 evaluable patients and 79% overall survival rate at 12-months - Based on the Company’s current operating... Full story

Yahoo Finance • 2 months ago

Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and anti... Full story

Yahoo Finance • 2 months ago

Merus NV stock hits all-time high, reaching 62.98 USD

Merus (NASDAQ:MRUS) NV stock reached an all-time high of 62.98 USD, marking a significant milestone for the biotechnology company. According to InvestingPro data, the stock is currently trading above analysts’ consensus Fair Value, with pr... Full story

Yahoo Finance • 3 months ago

Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III

Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the American Society of Clinical Oncology/ASCO, held in Chicago, the US, from May 30 to June 3, featured presentations on... Full story

Yahoo Finance • 4 months ago

Merus N.V.'s SWOT analysis: promising antibody platform drives stock potential

Merus N.V. (NASDAQ:MRUS), a clinical-stage oncology company valued at $4.1 billion, has been making waves in the biotechnology sector with its innovative multispecific antibody platform. The company’s lead candidate, petosemtamab, has show... Full story

Yahoo Finance • 4 months ago

Merus N.V. gibt Preis für öffentliches Angebot von Stammaktien bekannt

UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, June 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) („Merus“, das „Unternehmen“, „wir“ und „unser“), ein Onkologieunternehmen, das innovative, multispezifische Antikörper in vol... Full story

Yahoo Finance • 4 months ago

Merus N.V. gibt geplantes öffentliches Zeichnungsangebot von Stammaktien bekannt

UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, June 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) („Merus“, das „Unternehmen“, „wir“ und „unser“), ein Onkologieunternehmen, das innovative, multispezifische Antikörper in vol... Full story